A chimeric platelet-targeted urokinase prodrug selectively blocks new thrombus formation

Journal of Clinical Investigation

Volumn 126, Issue 2, 2016, Pages 483-494

  Fuentes, Rudy E ^a   Zaitsev, Sergei ^b   Ahn, Hyun Sook ^a   Hayes, Vincent ^a   Kowalska, M Anna ^a   Lambert, Michele P ^b   Wang, Yuhuan ^a   Siegel, Donald L ^b   Bougie, Daniel W ^c   Aster, Richard H ^c   Myers, Daniel D ^d   Stepanova, Victoria ^b   Cines, Douglas B ^b   Muzykantov, Vladimir R ^b   Poncz, Mortimer ^a,b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c BLOOD RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA IIB BETA3 MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY; PRODRUG; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; THROMBIN; UNCLASSIFIED DRUG; UROKINASE; HYBRID PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CLOT LYSIS; BLOOD CLOTTING; CONTROLLED STUDY; DRUG BINDING; DRUG HALF LIFE; GEL FILTRATION; IN VITRO STUDY; MICROFLUIDICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE MEMBRANE; ANIMAL; BLOOD; DRUG DELIVERY SYSTEM; GENETICS; HUMAN; KNOCKOUT MOUSE; METABOLISM; NONOBESE DIABETIC MOUSE; PROCEDURES; SCID MOUSE; THROMBOSIS;

ANIMALS; BLOOD PLATELETS; DRUG DELIVERY SYSTEMS; HUMANS; MICE; MICE, INBRED NOD; MICE, KNOCKOUT; MICE, SCID; PRODRUGS; RECOMBINANT FUSION PROTEINS; THROMBOSIS; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84956924316     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI81470     Document Type: Article

References (35)

1. Geerts WH, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;12(3 suppl):338S-400.
2. Stein PD, Kayali F, Olson RE. Estimated case fatality rate of pulmonary embolism, 1979 to 1998. Am J Cardiol. 2004;93(9):1197-1199.
3. Bell WR Jr. Evaluation of thrombolytic agents. Drugs. 1997;54(suppl 3):11-16.
4. Armstead WM, Cines DB, Higazi AA. Plasminogen activators contribute to impairment of hypercapnic and hypotensive cerebrovasodilation after cerebral hypoxia/ischemia in the newborn pig. Stroke. 2005;36(10):2265-2269.
5. Armstead WM, Cines DB, Bdeir KH, Bdeir Y, Stein SC, Higazi AA. uPA modulates the age-dependent effect of brain injury on cerebral hemodynamics through LRP and ERK MAPK. J Cereb Blood Flow Metab. 2009;29(3):524-533.
6. Simpson D, Siddiqui MA, Scott LJ, Hilleman DE. Reteplase: a review of its use in the management of thrombotic occlusive disorders. Am J Cardiovasc Drugs. 2006;6(4):265-285.
7. Agnelli G, Becattini C. Acute pulmonary embolism. N Engl J Med. 2010;363(3):266-274.
8. Zaitsev S, et al. Sustained thromboprophylaxis mediated by an RBC-targeted pro-urokinase zymogen activated at the site of clot formation. Blood. 2010;115(25):5241-5248.
9. Kahr WH, et al. Platelets from patients with the Quebec platelet disorder contain and secrete abnormal amounts of urokinase-type plasminogen activator. Blood. 2001;98(2):257-265.
10. Blavignac J, Bunimov N, Rivard GE, Hayward CP. Quebec platelet disorder: update on pathogenesis, diagnosis, and treatment. Semin Thromb Hemost. 2011;37 (6):713-720.
11. Kufrin D, et al. Antithrombotic thrombocytes: ectopic expression of urokinase-type plasminogen activator in platelets. Blood. 2003;102(3):926-933.
12. Erickson LA, Ginsberg MH, Loskutoff DJ. Detection and partial characterization of an inhibitor of plasminogen activator in human platelets. J Clin Invest. 1984;74(4):1465-1472.
13. Wagner CL, Mascelli MA, Neblock DS, Weisman HF, Coller BS, Jordan RE. Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets. Blood. 1996;88 (3):907-914.
14. Christensen U. Allosteric effects of some antifibrinolytic amino acids on the catalytic activity of human plasmin. Biochim Biophys Acta. 1978;526(1):194-201.
15. Thornton MA, Zhang C, Kowalska MA, Poncz M. Identification of distal regulatory regions in the human alpha IIb gene locus necessary for consistent, high-level megakaryocyte expression. Blood. 2002;100(10):3588-3596.
16. Margaritis P, Arruda VR, Aljamali M, Camire RM, Schlachterman A, High KA. Novel therapeutic approach for hemophilia using gene delivery of an engineered secreted activated Factor VII. J Clin Invest. 2004;113(7):1025-1031.
17. Arepally GM, et al. Characterization of a murine monoclonal antibody that mimics heparininduced thrombocytopenia antibodies. Blood. 2000;95(5):1533-1540.
18. Stalker TJ, et al. A systems approach to hemostasis: 3. Thrombus consolidation regulates intrathrombus solute transport and local thrombin activity. Blood. 2014;124(11):1824-1831.
19. Bode C, et al. Platelet-targeted fibrinolysis enhances clot lysis and inhibits platelet aggregation. Circulation. 1991;84(2):805-813.
20. Kohler M, et al. Half-life of single-chain urokinasetype plasminogen activator (scu-PA) and twochain urokinase-type plasminogen activator (tcu-PA) in patients with acute myocardial infarction. Thromb Res. 1991;62(1-2):75-81.
21. Hohmann JD, et al. Delayed targeting of CD39 to activated platelet GPIIb/IIIa via a singlechain antibody: breaking the link between antithrombotic potency and bleeding? Blood. 2013;121(16):3067-3075.
22. Wang X, et al. Towards effective safe thrombolysis thromboprophylaxis: preclinical testing of a novel antibody-targeted recombinant plasminogen activator directed against activated platelets. Circ Res. 2014;114(7):1083-1093.
23. Ito M, et al. NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood. 2002;100(9):3175-3182.
24. Bougie DW, Birenbaum J, Rasmussen M, Poncz M, Aster RH. Quinine-dependent, plateletreactive monoclonals mimic antibodies found in patients with quinine-induced immune thrombocytopenia. Blood. 2006;113(5):1105-1111.
25. Ding BS, et al. Prophylactic thrombolysis by thrombin-activated latent prourokinase targeted to PECAM-1 in the pulmonary vasculature. Blood. 2008;111(4):1999-2006.
26. Dobel S, et al. Isolation of IgG antibody Fv-DNA from various mouse and rat hybridoma cell lines using the polymerase chain reaction with a simple set of primers. J Immunol Methods. 1994;175(1):89-95.
27. Rauova L, et al. Monocyte-bound PF4 in the pathogenesis of heparin-induced thrombocytopenia. Blood. 2010;116(23):5021-5031.
28. Ding BS, et al. Endothelial targeting of a recombinant construct fusing a PECAM-1 single-chain variable antibody fragment (scFv) with prourokinase facilitates prophylactic thrombolysis in the pulmonary vasculature. Blood. 2005;106(13):4191-4198.
29. Yarovoi HV, et al. Factor VIII ectopically expressed in platelets: efficacy in hemophilia A treatment. Blood. 2003;102(12):4006-4013.
30. Greene TK, Schiviz A, Hoellriegl W, Poncz M, Muchitsch EM. Animal Models Subcommittee of the Scientific Standardization Committee of the ISTH. Towards a standardization of the murine tail bleeding model. J Thromb Haemost. 2010;8(12):2820-2822.
31. Ray GB, Blair HA, Thomas CI. The spectrophotometric determination of certain blood pigments. J Biol Chem. 1932;98:63-83.
32. Liu Y, Jennings NL, Dart AM, Du XJ. Standardizing a simpler, more sensitive and accurate tail bleeding assay in mice. World J Exp Med. 2012;2(2):30-36.
33. Neyman M, Gewirtz J, Poncz M. Analysis of the spatial and temporal characteristics of platelet-delivered factor VIII-based clots. Blood. 2008;112(4):1101-1108.
34. Courtney MA, Bunce LA, Neroni LA, Simpson-Haidaris PJ. Cloning of the complete coding sequence of rat fibrinogen B beta chain cDNA: interspecies conservation of fibrin beta 15-42 primary structure. Blood Coagul Fibrinolysis. 1994;5(4):487-496.
35. Falati S, Gross P, Merrill-Skoloff G, Furie BC, Furie B. Real-time in vivo imaging of platelets, tissue factor and fibrin during arterial thrombus formation in the mouse. Nat Med. 2002;8(10):1175-1181.